Functional magnetic resonance imaging of the liver: Parametric assessments beyond morphology

Magnetic Resonance Imaging Clinics of North America

Volumn 18, Issue 3, 2010, Pages 565-585

  Koh, Dow Mu ^a   Padhani, Anwar R ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Apparent diffusion coefficient; Dynamic contrast enhanced MR imaging; Functional MR imaging; Liver imaging; MR spectroscopy

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; GADOLINIUM;

ANISOTROPY; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMOEMBOLIZATION; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; ECHO PLANAR IMAGING; ELASTOGRAPHY; FATTY LIVER; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GAMMA KNIFE RADIOSURGERY; HEPATOGRAPHY; HISTOPATHOLOGY; HUMAN; IMAGE DISPLAY; IMAGE QUALITY; INTENSITY MODULATED RADIATION THERAPY; LIVER ANGIOGRAPHY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRCULATION; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER METASTASIS; LIVER RESECTION; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERFUSION WEIGHTED IMAGING; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; QUANTITATIVE DIAGNOSIS; RADIOLOGICAL PARAMETERS; REVIEW; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING; TISSUE OXYGENATION;

HUMANS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; MAGNETIC RESONANCE IMAGING;

EID: 78649287079     PISSN: 10649689     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mric.2010.07.002     Document Type: Review

References (90)

1. Padhani A.R., Choyke P.L. New techniques in oncologic imaging 2006, Taylor & Francis, New York.
2. Koh D.M., Collins D.J. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007, 188:1622-1635.
3. Patterson D.M., Padhani A.R., Collins D.J. Technology insight: water diffusion MRI-a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol 2008, 5:220-233.
4. Thoeny H.C., De Keyzer F. Extracranial applications of diffusion-weighted magnetic resonance imaging. Eur Radiol 2007, 17:1385-1393.
5. Payne G.S., Leach M.O. Applications of magnetic resonance spectroscopy in radiotherapy treatment planning. Br J Radiol 2006, 79(1):S16-S26.
6. Longo R., Pollesello P., Ricci C., et al. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging 1995, 5:281-285.
7. Szczepaniak L.S., Nurenberg P., Leonard D., et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005, 288:E462-E468.
8. Dixon W.T. Simple proton spectroscopic imaging. Radiology 1984, 153:189-194.
9. Rouviere O., Yin M., Dresner M.A., et al. MR elastography of the liver: preliminary results. Radiology 2006, 240:440-448.
10. Ehman R.L. Science to practice: can MR elastography be used to detect early steatohepatitis in fatty liver disease?. Radiology 2009, 253:1-3.
11. Huwart L., Sempoux C., Salameh N., et al. Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. Radiology 2007, 245:458-466.
12. Thng C.H., Koh T.S., Collins D.J., et al. Perfusion MR imaging of the liver. World J Gastroenterol 2010, 16:1598-1604.
13. Totman J.J., O'Gorman R.L., Kane P.A., et al. Comparison of the hepatic perfusion index measured with gadolinium-enhanced volumetric MRI in controls and in patients with colorectal cancer. Br J Radiol 2005, 78:105-109.
14. Tsushima Y., Blomley M.J., Yokoyama H., et al. Does the presence of distant and local malignancy alter parenchymal perfusion in apparently disease-free areas of the liver?. Dig Dis Sci 2001, 46:2113-2119.
15. Meijerink M.R., van Waesberghe J.H., van der Weide L., et al. Total-liver-volume perfusion CT using 3-D image fusion to improve detection and characterization of liver metastases. Eur Radiol 2008, 18:2345-2354.
16. Miyazaki M., Tsushima Y., Miyazaki A., et al. Quantification of hepatic arterial and portal perfusion with dynamic computed tomography: comparison of maximum-slope and dual-input one-compartment model methods. Jpn J Radiol 2009, 27:143-150.
17. Abdullah S.S., Pialat J.B., Wiart M., et al. Characterization of hepatocellular carcinoma and colorectal liver metastasis by means of perfusion MRI. J Magn Reson Imaging 2008, 28:390-395.
18. Sahani D.V., Holalkere N.S., Mueller P.R., et al. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue-initial experience. Radiology 2007, 243:736-743.
19. Miyazaki K., Collins D.J., Walker-Samuel S., et al. Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. Eur Radiol 2008, 18:1414-1421.
20. Chen G., Ma D.Q., He W., et al. Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2008, 14:5738-5743.
21. O'Connor J.P., Jackson A., Parker G.J., et al. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007, 96:189-195.
22. Mross K., Drevs J., Muller M., et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 2005, 41:1291-1299.
23. Thomas A.L., Morgan B., Horsfield M.A., et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005, 23:4162-4171.
24. Morgan B., Thomas A.L., Drevs J., et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003, 21:3955-3964.
25. Annet L., Materne R., Danse E., et al. Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology 2003, 229:409-414.
26. Leggett D.A., Kelley B.B., Bunce I.H., et al. Colorectal cancer: diagnostic potential of CT measurements of hepatic perfusion and implications for contrast enhancement protocols. Radiology 1997, 205:716-720.
27. Miles K.A., Hayball M.P., Dixon A.K. Functional images of hepatic perfusion obtained with dynamic CT. Radiology 1993, 188:405-411.
28. Koh T.S., Thng C.H., Hartono S., et al. Dynamic contrast-enhanced CT imaging of hepatocellular carcinoma in cirrhosis: feasibility of a prolonged dual-phase imaging protocol with tracer kinetics modeling. Eur Radiol 2009, 19:1184-1196.
29. Bammer R. Basic principles of diffusion-weighted imaging. Eur J Radiol 2003, 45:169-184.
30. Koh D.M., Takahara T., Imai Y., et al. Practical aspects of assessing tumors using clinical diffusion-weighted imaging in the body. Magn Reson Med Sci 2007, 6:211-224.
31. Girometti R., Furlan A., Bazzocchi M., et al. Radiol Med 2007, 112:394-408. [in Italian].
32. Girometti R., Furlan A., Esposito G., et al. Relevance of b-values in evaluating liver fibrosis: a study in healthy and cirrhotic subjects using two single-shot spin-echo echo-planar diffusion-weighted sequences. J Magn Reson Imaging 2008, 28:411-419.
33. Aube C., Racineux P.X., Lebigot J., et al. J Radiol 2004, 85:301-306. [in French].
34. Koinuma M., Ohashi I., Hanafusa K., et al. Apparent diffusion coefficient measurements with diffusion-weighted magnetic resonance imaging for evaluation of hepatic fibrosis. J Magn Reson Imaging 2005, 22:80-85.
35. Lewin M., Poujol-Robert A., Boelle P.Y., et al. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 2007, 46:658-665.
36. Boulanger Y., Amara M., Lepanto L., et al. Diffusion-weighted MR imaging of the liver of hepatitis C patients. NMR Biomed 2003, 16:132-136.
37. Taouli B., Tolia A.J., Losada M., et al. Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience. AJR Am J Roentgenol 2007, 189:799-806.
38. Taouli B., Chouli M., Martin A.J., et al. Chronic hepatitis: role of diffusion-weighted imaging and diffusion tensor imaging for the diagnosis of liver fibrosis and inflammation. J Magn Reson Imaging 2008, 28:89-95.
39. Luciani A., Vignaud A., Cavet M., et al. Liver cirrhosis: intravoxel incoherent motion MR imaging-pilot study. Radiology 2008, 249:891-899.
40. Parikh T., Drew S.J., Lee V.S., et al. Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology 2008, 246:812-822.
41. Bruegel M., Gaa J., Waldt S., et al. Diagnosis of hepatic metastasis: comparison of respiration-triggered diffusion-weighted echo-planar MRI and five t2-weighted turbo spin-echo sequences. AJR Am J Roentgenol 2008, 191:1421-1429.
42. Bruegel M., Holzapfel K., Gaa J., et al. Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. Eur Radiol 2008, 18:477-485.
43. Zech C.J., Herrmann K.A., Dietrich O., et al. Black-blood diffusion-weighted EPI acquisition of the liver with parallel imaging: comparison with a standard T2-weighted sequence for detection of focal liver lesions. Invest Radiol 2008, 43:261-266.
44. Nasu K., Kuroki Y., Nawano S., et al. Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 2006, 239:122-130.
45. Koh D.M., Brown G., Riddell A.M., et al. Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination. Eur Radiol 2008, 18(5):903-910.
46. Namimoto T., Yamashita Y., Sumi S., et al. Focal liver masses: characterization with diffusion-weighted echo-planar MR imaging. Radiology 1997, 204:739-744.
47. Ichikawa T., Haradome H., Hachiya J., et al. Diffusion-weighted MR imaging with a single-shot echoplanar sequence: detection and characterization of focal hepatic lesions. AJR Am J Roentgenol 1998, 170:397-402.
48. Kim T., Murakami T., Takahashi S., et al. Diffusion-weighted single-shot echoplanar MR imaging for liver disease. AJR Am J Roentgenol 1999, 173:393-398.
49. Taouli B., Vilgrain V., Dumont E., et al. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 2003, 226:71-78.
50. Gourtsoyianni S., Papanikolaou N., Yarmenitis S., et al. Respiratory gated diffusion-weighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions. Eur Radiol 2008, 18:486-492.
51. Taouli B., Koh D.M. Diffusion-weighted MR imaging of the liver. Radiology 2010, 254:47-66.
52. Nasu K., Kuroki Y., Tsukamoto T., et al. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. AJR Am J Roentgenol 2009, 193:438-444.
53. Muhi A., Ichikawa T., Motosugi U., et al. High-b-value diffusion-weighted MR imaging of hepatocellular lesions: estimation of grade of malignancy of hepatocellular carcinoma. J Magn Reson Imaging 2009, 30:1005-1011.
54. Cui Y., Zhang X.P., Sun Y.S., et al. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008, 248:894-900.
55. Koh D.M., Blackledge M., Collins D.J., et al. Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 2009, 19:2728-2738.
56. Schraml C., Schwenzer N.F., Martirosian P., et al. Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol 2009, 193:W301-W307.
57. Koh D.M., Scurr E., Collins D., et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol 2007, 188:1001-1008.
58. Sijens P.E., Smit G.P., Borgdorff M.A., et al. Multiple voxel 1H MR spectroscopy of phosphorylase-b kinase deficient patients (GSD IXa) showing an accumulation of fat in the liver that resolves with aging. J Hepatol 2006, 45:851-855.
59. Thomsen C., Becker U., Winkler K., et al. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging 1994, 12:487-495.
60. Lee S.S., Park S.H., Kim H.J., et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol 2010, 52:579-585.
61. Machann J., Thamer C., Schnoedt B., et al. Hepatic lipid accumulation in healthy subjects: a comparative study using spectral fat-selective MRI and volume-localized 1H-MR spectroscopy. Magn Reson Med 2006, 55:913-917.
62. Menon D.K., Sargentoni J., Taylor-Robinson S.D., et al. Effect of functional grade and etiology on in vivo hepatic phosphorus-31 magnetic resonance spectroscopy in cirrhosis: biochemical basis of spectral appearances. Hepatology 1995, 21:417-427.
63. van Wassenaer-van Hall H.N., van der Grond J., van Hattum J., et al. 31P magnetic resonance spectroscopy of the liver: correlation with standardized serum, clinical, and histological changes in diffuse liver disease. Hepatology 1995, 21:443-449.
64. Dagnelie P.C., Leij-Halfwerk S. Magnetic resonance spectroscopy to study hepatic metabolism in diffuse liver diseases, diabetes and cancer. World J Gastroenterol 2010, 16:1577-1586.
65. Sijens P.E. Parametric exploration of the liver by magnetic resonance methods. Eur Radiol 2009, 19:2594-2607.
66. Kuo Y.T., Li C.W., Chen C.Y., et al. In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner. J Magn Reson Imaging 2004, 19:598-604.
67. Soper R., Himmelreich U., Painter D., et al. Pathology of hepatocellular carcinoma and its precursors using proton magnetic resonance spectroscopy and a statistical classification strategy. Pathology 2002, 34:417-422.
68. Kim H., Taksali S.E., Dufour S., et al. Comparative MR study of hepatic fat quantification using single-voxel proton spectroscopy, two-point Dixon and three-point IDEAL. Magn Reson Med 2008, 59:521-527.
69. Westphalen A.C., Qayyum A., Yeh B.M., et al. Liver fat: effect of hepatic iron deposition on evaluation with opposed-phase MR imaging. Radiology 2007, 242:450-455.
70. Reeder S.B., Pineda A.R., Wen Z., et al. Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL): application with fast spin-echo imaging. Magn Reson Med 2005, 54:636-644.
71. Costa D.N., Pedrosa I., McKenzie C., et al. Body MRI using IDEAL. AJR Am J Roentgenol 2008, 190:1076-1084.
72. Reeder S.B., McKenzie C.A., Pineda A.R., et al. Water-fat separation with IDEAL gradient-echo imaging. J Magn Reson Imaging 2007, 25:644-652.
73. Reeder S.B., Hargreaves B.A., Yu H., et al. Homodyne reconstruction and IDEAL water-fat decomposition. Magn Reson Med 2005, 54:586-593.
74. Szumowski J., Coshow W.R., Li F., et al. Phase unwrapping in the three-point Dixon method for fat suppression MR imaging. Radiology 1994, 192:555-561.
75. Szumowski J., Coshow W., Li F., et al. Double-echo three-point-Dixon method for fat suppression MRI. Magn Reson Med 1995, 34:120-124.
76. Coombs B.D., Szumowski J., Coshow W. Two-point Dixon technique for water-fat signal decomposition with B0 inhomogeneity correction. Magn Reson Med 1997, 38:884-889.
77. Angelucci E., Giovagnoni A., Valeri G., et al. Limitations of magnetic resonance imaging in measurement of hepatic iron. Blood 1997, 90:4736-4742.
78. Christoforidis A., Perifanis V., Spanos G., et al. MRI assessment of liver iron content in thalassamic patients with three different protocols: comparisons and correlations. Eur J Haematol 2009, 82:388-392.
79. Gandon Y., Olivie D., Guyader D., et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004, 363:357-362.
80. Wood J.C., Enriquez C., Ghugre N., et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005, 106:1460-1465.
81. Kaltwasser J.P., Gottschalk R., Schalk K.P., et al. Non-invasive quantitation of liver iron-overload by magnetic resonance imaging. Br J Haematol 1990, 74:360-363.
82. Huwart L., Peeters F., Sinkus R., et al. Liver fibrosis: non-invasive assessment with MR elastography. NMR Biomed 2006, 19:173-179.
83. Yin M., Talwalkar J.A., Glaser K.J., et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007, 5:1207-1213. e1202.
84. Asbach P., Klatt D., Hamhaber U., et al. Assessment of liver viscoelasticity using multifrequency MR elastography. Magn Reson Med 2008, 60:373-379.
85. Klatt D., Asbach P., Rump J., et al. In vivo determination of hepatic stiffness using steady-state free precession magnetic resonance elastography. Invest Radiol 2006, 41:841-848.
86. Tsui E.Y., Chan J.H., Cheung Y.K., et al. Evaluation of therapeutic effectiveness of transarterial chemoembolization for hepatocellular carcinoma: correlation of dynamic susceptibility contrast-enhanced echoplanar imaging and hepatic angiography. Clin Imaging 2000, 24:210-216.
87. Rhee T.K., Larson A.C., Prasad P.V., et al. Feasibility of blood oxygenation level-dependent MR imaging to monitor hepatic transcatheter arterial embolization in rabbits. J Vasc Interv Radiol 2005, 16:1523-1528.
88. O'Connor J.P., Naish J.H., Parker G.J., et al. Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumors. Int J Radiat Oncol Biol Phys 2009, 75:1209-1215.
89. Taouli B., Martin A.J., Qayyum A., et al. Parallel imaging and diffusion tensor imaging for diffusion-weighted MRI of the liver: preliminary experience in healthy volunteers. AJR Am J Roentgenol 2004, 183:677-680.
90. Guiu B., Loffroy R., Hillon P., et al. Magnetic resonance imaging and spectroscopy for quantification of hepatic steatosis: urgent need for standardization!. J Hepatol 2009, 51:1082-1083. [author reply: 1083-4].